PUBMED ARTICLES
Clinical studies and cases
Influenza viruses | Dengue viruses:
- Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study
- The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.
- Fatal Dengue in Patients with Sickle Cell Disease of Sickle Cell Anemia in Curacao: two case reports.
- Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome.
Other Viruses
- Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season
- First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial
- Fatal human rabies due to Duvenhage virus from a bat in Kenya: failure of treatment with coma-induction, ketamine, and antiviral drugs.
- Norovirus in a Dutch tertiary care hospital (2002-2007): frequent nosocomial transmission and dominance of GIIb strains in young children.
- Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2.
Virus discovery, new previously unidentified viruses in man and animals
Indentifying emerging pathogens | Deep sequencing:
- Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study.
- Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
- Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.
- Novel hepatitis E virus in ferrets, the Netherlands.
- Picobirnaviruses in the Human Respiratory Tract.
- High prevalence of anelloviruses in vitreous fluid of children with seasonal hyperacute panuveitis.
- Metagenomic analysis of the viral flora of pine marten and European badger feces.
- Calicivirus from novel recovirus genogroup in human diarrhea, bangladesh.
- Genogroup I and II picobirnaviruses in respiratory tracts of pigs.
- Enteric coronavirus in ferrets, The Netherlands.
- Identification and characterization of deer astroviruses.
- Human picobirnaviruses identified by molecular screening of diarrhea samples.
- Human astrovirus infection in a patient with new-onset celiac disease.
- A previously undescribed coronavirus associated with respiratory disease in humans.
Animal model development: other species / other viruses, etc.
Ferrets | Rabbits | Cats | Non-human primates:
- Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2
- AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets
- Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
- Susceptibility of rabbits to SARS-CoV-2
- Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates
- Inhibition of caspase-1 prolongs survival of mice infected with rabies virus
- Analysis of Mouse Brain Transcriptome After Experimental Duvenhage Virus Infection Shows Activation of Innate Immune Response and Pyroptotic Cell Death Pathway
- Low pathogenic avian influenza A(H7N9) virus causes high mortality in ferrets upon intratracheal challenge: A model to study intervention strategies.
- Animal models.
- Distinct SARS-Coronavirus Induced Acute Lung Injury Pathways in Two Different Non-Human Primate Species.
- Experimental pandemic (H1N1) 2009 virus infection of cats.
- Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
- Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine.
Animal model development: novel approaches
Immunocompromised ferret model | In vivo imaging | Rapid development of animal models for emerging viruses:
- Transmission of Human Respiratory Syncytial Virus in the Immunocompromised Ferret Model
- Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets.
- Modification of the ferret model for pneumonia from seasonal human influenza a virus infection.
- Pulmonary pathology of pandemic influenza A/H1N1 virus (2009)-infected ferrets upon longitudinal evaluation by computed tomography.
- Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus.
- Experimental pandemic (H1N1) 2009 virus infection of cats.
Vaccine immunogenicity- and efficacy testing in ferrets
Humoral immune responses (ELISA, Virus Neutralization, Plaque Reduction, Haemagglutination Inhibition, etc. ) | Cell-mediated immune responses | Prime-boost strategies | Production of hyper immune serum | Longevity of protection | Dose-finding, Dose-optimization | Clinical scoring:
- Immunogenicity and efficacy comparison of MDCK cell-based and egg-based live attenuated influenza vaccines of H5 and H7 subtypes in ferrets
- Immunogenicity and efficacy of the monovalent, trivalent and quadrivalent intranasal live attenuated influenza vaccines containing different pdmH1N1 strains
- Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic Influenza Intranasal and Intratracheal Challenge.
- Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.
- Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
- Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets.
- A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets.
- Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
- Seasonal influenza vaccine provides priming for A/H1N1 immunization.
- Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
Antiviral efficacy and pharmaco kinetics testing in ferrets
Prophylaxis and Therapy (delayed treatment) | (Deep) sequencing, mutation-specific PCR | Any route of drug administration possible (IV, oral, nebulizer, etc.) | Read outs include: clinical scoring (signs of disease, body temperature, lung function, etc), viral loads (by quantitative PCR and virus titration), gross pathology, histopathology, immune histochemistry, etc. | Virus transmission:
- Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets.
- New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.
- Delayed oseltamivir treatment of influenza virus A/turkey/Turkey/1/2005 (H5N1) infection in ferrets.
Antiviral efficacy testing and pk analysis in non-human primates
Prophylaxis and Therapy (delayed treatment) | (Deep) sequencing, mutation-specific PCR | Any route of drug administration possible (IV, oral, nebulizer, etc.) | Read outs include: clinical scoring (signs of disease, body temperature, lung function, etc), viral loads (by quantitative PCR and virus titration), gross pathology, histopathology, immune histochemistry, etc.:
Vaccine immunogenicity- and efficacy testing in non-human primates
Active- and passive immunization strategies | Read outs include: antibody responses, cell-mediated immune responses, clinical scoring (signs of disease, body temperature, lung function, etc), viral loads (by quantitative PCR and virus titration), gross pathology, histopathology, immune histochemistry, etc.:
- Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
- Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement.
- Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.
- Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
R&D / Assay Development
Academic peer reviewed publications focused on assay innovation.
- Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
- ViroSpot microneutralization assay for antigenic characterization of human influenza viruses.
- Establishment of the first WHO International Standard for antiserum to Respiratory Syncytial Virus: Report of an international collaborative study.
Polio Eradication
Academic peer reviewed publications focused on polio viruses.
